drugset
drugset / Trial / NCT00120393

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

NCT00120393 ↗

Phase 3 Completed 192 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside reverse transcriptase inhibitors (NRTIs).

Timeline

Start
2004-01
Primary completion
2006-05
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 300 mg Oral
Comparator Lopinavir Other / unclassified 400 mg Oral
Comparator Ritonavir Other / unclassified 100 mg Oral

Indications

HIV infectious disease